Miele Monica, Gallo Alessia, Di Bella Mariangela, Timoneri Francesca, Barbera Floriana, Sciveres Marco, Riva Silvia, Grossi Paolo, Conaldi Pier Giulio
Department of Research, IRCCS ISMETT (Istituto Mediterraneo per i Trapianti e Terapie ad Alta Specializzazione), Via E. Tricomi 5, 90127 Palermo, Italy.
Fondazione Ri.MED, 90133 Palermo, Italy.
Microorganisms. 2021 Mar 26;9(4):684. doi: 10.3390/microorganisms9040684.
Cytomegalovirus (CMV) infection is the most significant viral infection in hosts with compromised immune systems as solid organ transplant patients. Despite significant progress being made in the prevention of CMV disease in these patients, further therapeutic strategies for CMV disease and for the CMV reactivation prevention are needed. Here, we describe the outcome of the infusion of in vitro expanded CMV-reactive T-cells, taken from a healthy CMV-seropositive donor, in a liver-transplanted recipient with a refractory recurrent CMV. In this particular case, adoptive transfer of allogenic CMV-reactive T-lymphocytes resulted in the clearance of CMV infection and resolution of the pathological manifestations of the patient. In the study we also investigated circulating miRNAs, both cellular and viral, as potential biomarkers during the course of CMV infection. The results indicate that the infusion of allogenic CMV-reactive T-cells can be an effective strategy to treat CMV infection recurrence when the generation of autologous virus specific T cell clones is not possible.
巨细胞病毒（CMV）感染是实体器官移植患者等免疫系统受损宿主中最严重的病毒感染。尽管在预防这些患者的CMV疾病方面取得了重大进展，但仍需要针对CMV疾病和预防CMV再激活的进一步治疗策略。在此，我们描述了从健康的CMV血清阳性供体获取的体外扩增的CMV反应性T细胞输注到患有难治性复发性CMV的肝移植受者体内的结果。在这个特殊病例中，同种异体CMV反应性T淋巴细胞的过继转移导致了CMV感染的清除以及患者病理表现的消退。在该研究中，我们还研究了循环中的细胞和病毒miRNA，作为CMV感染过程中的潜在生物标志物。结果表明，当无法产生自体病毒特异性T细胞克隆时，输注同种异体CMV反应性T细胞可能是治疗CMV感染复发的有效策略。
